PMC9294358_01
Treatment timeline of the patient. Progressive lesions are indicated by red arrows. PD, progressive disease; PR, partial response; SD, stable disease.
fonc-12-911961-g001.jpg
PMC9294358_01_fonc-12-911961-g001.jpg
f1
The workup was pursued by a computed tomography (CT) scan, which showed a right lung mass (3.6 cm x 3.7 cm), a hepatic lump (2.2 cm x 1.5 cm) next to the inferior vena cava, and enlarged retroperitoneal lymph nodes ( Figure 1 ). Unfortunately, on September 15, 2020, a whole-body CT scan showed a progressive disease with an increase in the diameter of the right lung lesion (4.6 cm x 4.2 cm) ( Figure 1 ). After 3 cycles of camrelizumab, the patient was evaluated as with partial response for both PSC (3.1 cm x 3.1 cm) and HCC (1.4 cm x 1.2 cm) on the basis of CT imaging on December 15, 2020 ( Figure 1 ). Both PSC and HCC were assessed as stable disease (SD) ( Figure 1 ). Unfortunately, on June 16, 2021, the patient was assessed as PD with an increase of live tumor (the longer diameter is 1.5 cm) associated with the rise of AFP ( Figure 2 ) and the significant enlargement of abdominal lymph nodes in a whole-body CT scan ( Figure 1 ). After 23 cycles of camrelizumab treatment, the efficacy was assessed as SD for PSC and HCC according to the CT scan image in the last follow-up ( Figure 1 ).
Changes of serum AFP level during camrelizumab treatment. AFP, alpha-fetoprotein.
fonc-12-911961-g002.jpg
PMC9294358_01_fonc-12-911961-g002.jpg
f2
Unfortunately, on June 16, 2021, the patient was assessed as PD with an increase of live tumor (the longer diameter is 1.5 cm) associated with the rise of AFP ( Figure 2 ) and the significant enlargement of abdominal lymph nodes in a whole-body CT scan ( Figure 1 ).